The CLDN18.2-targeted antibody zolbetuximab is approved for the treatment of locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma in adults with CLDN18.2-positive tumors. The gene discussed is CLDN18; the disease is gastroesophageal junction adenocarcinoma.